# A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

> **NCT03558152** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 195 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** UTTR1147A
- **DRUG:** UTTR1147A Placebo
- **DRUG:** Vedolizumab
- **DRUG:** Vedolizumab Placebo

## Key facts

- **NCT ID:** NCT03558152
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-26
- **Primary completion:** 2021-12-15
- **Final completion:** 2021-12-15
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03558152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03558152, "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03558152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*